Here are 1-3 brief analogies for Metagenomi Therapeutics (MGX):

• Metagenomi is like a 'CRISPR 2.0' company, but with a vastly more diverse and precise toolkit for gene editing, all discovered from nature's microbial world.
• Metagenomi is like 'the hardware store for genome editing,' building a comprehensive suite of advanced tools to fix any genetic mutation, by mining novel systems from diverse microbial environments.

• Proprietary Genome Editing Toolbox: A comprehensive and modular suite of novel genome editing systems, including programmable nucleases, base editors, and RNA/DNA-mediated integration systems, discovered through metagenomics to correct diverse genetic mutations.
• Hemophilia A Gene Therapy Candidate: A preclinical therapeutic candidate designed to achieve durable Factor VIII expression via a novel, targeted gene knock-in approach.
• Primary Hyperoxaluria Type 1 (PH1) Gene Therapy Candidate: A preclinical therapeutic candidate aimed at durable substrate reduction by knocking down the HAO1 gene in the liver.
• Transthyretin Amyloidosis (ATTR) Gene Therapy Candidate: A preclinical therapeutic candidate developed to halt amyloid fibril deposition through a single treatment that knocks down TTR gene expression.

Metagenomi Therapeutics (MGX) is a precision genetic medicines company focused on the research and development of curative therapeutics. Based on the provided background information, the company explicitly states: "While we do not currently have any approved products and all of our product candidates are preclinical".

Therefore, Metagenomi Therapeutics does not currently have major customers, as it is in the preclinical stage of developing its therapeutic candidates and does not yet sell products or services.

The company does engage in strategic partnerships for the co-development of its therapeutic programs. These partners include:

• ModernaTX, Inc. (MRNA) - Partner for the Primary Hyperoxaluria, Type 1 (PH1) program.
• Ionis Pharmaceuticals, Inc. (IONS) - Partner for the Transthyretin Amyloidosis program.

These entities are collaborators in drug development rather than customers purchasing Metagenomi's products or services.

Jian Irish, PhD, MBA President and Chief Executive Officer

Jian Irish was appointed President and Chief Executive Officer of Metagenomi Therapeutics in November 2025. Prior to this, she served as President and Chief Operating Officer of the company. She brings over 25 years of leadership experience in biopharma operations, with executive responsibilities in drug development and commercialization, organization building, and global business operations. Her career includes executive leadership roles at Kite Pharma, where she was instrumental in launching one of the first approved CAR-T cell therapy products and scaling cell therapy operations as Senior Vice President, Global Head of Manufacturing, and Senior Vice President of Supply Chain. Before joining Kite, Dr. Irish was Vice President for biologics product development, supply, and partnerships at Sanofi. She also held executive leadership roles at Amgen for 15 years, focusing on oncology development, manufacturing, and JAPAC regional operations, contributing to the launch of numerous innovative medicines. Dr. Irish holds a PhD in Pharmaceutical Sciences from Chiba University, a BS in Chemical Engineering from East China University of Science and Technology, and an MBA from the Anderson School of Management at UCLA.

Pamela Wapnick, MBA Chief Financial Officer

Pamela Wapnick was appointed Chief Financial Officer of Metagenomi in November 2023. She possesses over 20 years of diversified financial leadership experience, encompassing strategic and operational finance roles. Ms. Wapnick has previously served as Chief Financial Officer at several biotech and medical technology companies, including Diality, Capsida Biotherapeutics, and Graybug Vision, where she established finance functions and led financial planning and strategy. Notably, as CFO at True North Therapeutics, she managed the preparations for an initial public offering before the company's acquisition by Bioverativ.

Matthew Wein, JD General Counsel, Compliance Officer, Head of BD&L & Corporate Secretary

Matthew Wein serves as General Counsel, Compliance Officer, Head of BD&L & Corporate Secretary at Metagenomi. He has over 20 years of experience providing strategic guidance and legal counsel to publicly-traded biotech and pharmaceutical companies across preclinical, clinical, and commercial stages of operations. Most recently, Mr. Wein was General Counsel and Corporate Secretary of Mustang Bio, Inc., a public clinical-stage gene and cell therapy company. Before Mustang, he was a Senior Director at Sanofi, where he managed strategic alliances across various businesses, including biologics and biosimilars, gene therapies, consumer healthcare products, and "smart" devices. He also held various leadership roles supporting global operations and key collaborations as Senior Counsel during his 14-year tenure at Amgen. Mr. Wein earned his law degree from the University of Southern California and is a member of the Bar in California and Massachusetts.

Alan Brooks, PhD Senior Vice President of Research

Alan Brooks is the Senior Vice President of Research at Metagenomi, where he oversees the company's in vivo therapeutic gene editing programs. He brings more than 30 years of leadership experience in the biotech and pharmaceutical industries, specializing in drug discovery with a focus on gene therapies and gene editing. Prior to joining Metagenomi in November 2019, Dr. Brooks was a Principal Scientist at Casebia Therapeutics, where he initiated and led CRISPR/Cas9 genome editing projects for hematology. Earlier in his career, he led projects in gene therapy and protein therapeutics, with a focus on Hemophilia and rare hematological disorders, during his 10 years at Bayer Healthcare. He also worked at several biotech startups focused on cardiovascular and neurological diseases. Dr. Brooks received his Bachelor of Science from the University of Leicester and his Ph.D. in molecular biology from the University of Warwick.

Katalin Kauser, PhD, MD, Sc.D Senior Vice President of Translational Biology

Katalin Kauser is the Senior Vice President of Translational Biology at Metagenomi. She brings over 30 years of leadership experience in the biotech and pharmaceutical industries, specializing in drug discovery and preclinical development from target identification and validation through regulatory submission and early clinical development. Her extensive experience spans multiple therapeutic areas, including hematology, cardiovascular, pulmonary, and metabolic diseases, and various modalities such as small molecules, biologics, gene therapy, and medical devices. Before joining Metagenomi, Dr. Kauser held executive and scientific leadership positions at Alucent Biomedical, Global Blood Therapeutics, Bayer, Boehringer Ingelheim, and Berlex Biosciences. She received her MD from Semmelweis Medical University and her PhD and DSc from the Hungarian Academy of Sciences in Budapest, Hungary.

1. High Risk of Clinical and Regulatory Failure for Preclinical Programs: Metagenomi Therapeutics currently has no approved products, and all of its product candidates are in preclinical stages. This inherently carries substantial risk that their investigational therapies may not demonstrate sufficient safety, efficacy, or durability in human clinical trials to warrant regulatory approval, a common challenge in the development of novel genetic medicines. The company is still in the process of generating robust long-term durability data in non-human primate studies for its lead programs, such as Hemophilia A.
2. Unproven Efficacy, Durability, and Safety of Novel Genome Editing Tools in Humans: The company's core business relies on its "proprietary, comprehensive metagenomics-derived genome editing toolbox," which includes novel programmable nucleases, base editors, and RNA and DNA-mediated integration systems. While preclinical data is promising and the company aims to overcome limitations of first-generation CRISPR/Cas9 systems, the actual long-term efficacy, durability, specificity, and safety profiles of these novel tools in human beings remain unproven. Unexpected off-target effects, immunogenicity, or insufficient therapeutic benefit could emerge during human trials.
3. Technical Challenges in Achieving Large Genomic Integrations: Metagenomi acknowledges that its "Big RIGS and CASTs are novel genome editing systems that are under development to achieve what has been a major challenge for the genome editing field—large, targeted genomic integrations." The successful development and translation of these systems for integrating complete and functional genes (e.g., for cystic fibrosis) is critical for addressing a wide range of loss-of-function mutations, and failure to overcome these technical hurdles could significantly limit their therapeutic potential.

The clear emerging threat for Metagenomi Therapeutics (MGX) is the rapid development and clinical advancement by competitors of alternative, non-metagenomics-derived gene editing platforms. MGX's core value proposition is built on its proprietary, metagenomics-derived toolbox designed to overcome the limitations of "first-generation CRISPR/Cas9 systems" in terms of targetability, specificity, size for delivery (e.g., AAV compatibility), and the ability to achieve large, targeted genomic integrations (e.g., Big RIGS and CASTs). If other companies, using different discovery methods (e.g., synthetic biology, directed evolution, or advanced computational design), introduce genome editing systems that match or surpass MGX's claimed advantages in these critical areas, it would diminish the unique competitive differentiation and potential market lead of Metagenomi's approach.

• Hemophilia A: The global patient population is estimated to be over 500,000, with up to 26,500 patients in the U.S.. No market size in USD was provided.
• Primary Hyperoxaluria, Type 1 (PH1): Null
• Transthyretin Amyloidosis (ATTRv and ATTRwt): Globally, there are an estimated 50,000 patients with hereditary transthyretin amyloidosis (ATTRv) and between 300,000 and 500,000 patients with wild-type ATTR amyloidosis (ATTRwt). The global transthyretin amyloidosis treatment market size was valued at approximately $7.7 billion in 2025 and is projected to reach $25.37 billion by 2034.
• Wilson’s Disease: Null
• Alpha-1 Antitrypsin Deficiency (A1AT Deficiency): The global Alpha-1 Antitrypsin Deficiency market was valued at approximately $3.57 billion in 2025 and is projected to reach $9.64 billion by 2032.
• Amyotrophic Lateral Sclerosis (ALS): The global Amyotrophic Lateral Sclerosis therapeutics market is projected to reach a valuation of approximately $1.053 billion in 2025 and $1.964 billion by 2034. In the U.S., the market size for ALS was $800 million in 2024.
• Charcot-Marie-Tooth Type 1a (CMT1A): The global Charcot-Marie-Tooth disease market size reached $814.5 million in 2023 and is expected to reach $8.995 billion by 2034.
• Duchenne Muscular Dystrophy (DMD): The global Duchenne Muscular Dystrophy treatment market size was valued at approximately $4.63 billion in 2025 and is projected to reach $19.18 billion by 2034.
• Cystic Fibrosis (CF): The global cystic fibrosis therapeutics market size is estimated at $13.88 billion in 2025 and is projected to reach approximately $35.68 billion by 2035.

Metagenomi Therapeutics (MGX) is a precision genetic medicines company focused on developing curative therapeutics using its proprietary genome editing toolbox. As a preclinical-stage company, its future revenue growth over the next 2-3 years is expected to be driven primarily by the achievement of developmental milestones and the expansion of its strategic partnerships. The key drivers include:

1. Advancement of Lead Therapeutic Programs: Metagenomi's pipeline includes lead programs for Hemophilia A, Primary Hyperoxaluria Type 1 (PH1), and Transthyretin Amyloidosis. Moving these programs through preclinical development, into non-human primate (NHP) studies, and towards Investigational New Drug (IND) enabling studies and subsequent clinical trials, is a significant revenue driver. For instance, the company anticipates development candidate selection for Hemophilia A in Q2 2024 and expects NHP data for PH1 and Transthyretin Amyloidosis in 2024. Such progress will likely trigger milestone payments from existing partners and enhance the value proposition for potential new collaborations.
2. Expansion of Strategic Partnerships and Collaborations: The company's comprehensive metagenomics-derived genome editing toolbox, which includes programmable nucleases, base editors, and RNA/DNA-mediated integration systems (RIGS and CASTs), positions it to form new strategic alliances. Leveraging its diverse and modular platform for additional therapeutic targets or disease areas beyond its current lead programs could generate significant upfront payments, research funding, and future milestone payments from new partners.
3. Achievement of Milestones in Existing Collaborations: Metagenomi has established partnerships with ModernaTX, Inc. for PH1 and Ionis Pharmaceuticals, Inc. for Transthyretin Amyloidosis. The successful achievement of preclinical and early clinical milestones within these collaborations, such as positive NHP study results and the initiation of IND-enabling studies, is contractually tied to milestone payments, directly contributing to revenue growth. For example, the company has achieved preclinical proof-of-concept for PH1 with Moderna and over 90% knockdown of human TTR protein in a humanized mouse model with Ionis.
4. Expansion of the Therapeutic Pipeline into New Indications and Advanced Editing Systems: Beyond its lead programs, Metagenomi is actively exploring extrahepatic indications, including neurodegenerative and neuromuscular diseases, as well as liver diseases like Wilson's disease and Alpha-1 Antitrypsin Deficiency (A1AT). Furthermore, the development and application of its larger RNA- and DNA-mediated integration systems (Big RIGS and CASTs) for complex conditions like Cystic Fibrosis represent a significant opportunity. Progress in these areas, even at the preclinical stage, could lead to new research collaborations or expansion of existing partnerships, generating additional revenue streams.

Share Issuance

• Metagenomi Therapeutics completed its Initial Public Offering (IPO) on February 13, 2024, issuing 6,250,000 shares of common stock at a price of $15.00 per share.
• As of December 31, 2025, the weighted average common shares outstanding, basic and diluted, were approximately 37.3 million.

Inbound Investments

• Collaboration revenue for Metagenomi Therapeutics was $25.2 million in 2025.
• The company has collaboration agreements with strategic partners such as ModernaTX, Inc. and Ionis Pharmaceuticals, Inc.
• Deferred revenue, reflecting ongoing recognition under the Ionis collaboration, totaled $14.8 million as of September 30, 2025.

Capital Expenditures

• Capital expenditures for Metagenomi Therapeutics were -$574,000 in the last 12 months, encompassing most of 2025.
• In Q4 2025, the company invested $85,000 in capital expenditures, which are focused on funding long-term assets and infrastructure.